Takeda Cements Norovirus Lead Through Vaccine Trial Start
This article was originally published in PharmAsia News
Takeda has initiated dosing in the first field trial globally with a candidate vaccine for norovirus, maintaining its clear development lead in the area.
You may also be interested in...
Although norovirus infections are implicated in roughly 200,000 deaths per year, there are only four candidates in clinical development, Datamonitor Healthcare notes. This may be due partly to challenges posed by the virus' strain diversity and a lack of epidemiologic data.
While Sanofi late last year became the first company to commercialize a vaccine for dengue, Takeda has strengthened its position as the likely next to market contender following the start of a global Phase III program for its rival product.
In this week's podcast edition of Five Must-Know Things: a look at Alzheimer’s drug development; US-China decoupling irks Chinese biotech firms; seven potential blockbuster approvals in 2023; Novo Nordisk’s cardiovascular strategy; and a look at the vaccine and drug pipeline for monkeypox.